489 related articles for article (PubMed ID: 17312332)
41. Recombinant human erythropoietin and platinum-based chemotherapy in advanced ovarian cancer.
Welch RS; James RD; Wilkinson PM; Belli F; Cowan RA
Cancer J Sci Am; 1995; 1(4):261-6. PubMed ID: 9166486
[TBL] [Abstract][Full Text] [Related]
42. Epoetin alfa for the treatment of the anemia of multiple myeloma. A prospective, randomized, placebo-controlled, double-blind trial.
Garton JP; Gertz MA; Witzig TE; Greipp PR; Lust JA; Schroeder G; Kyle RA
Arch Intern Med; 1995 Oct; 155(19):2069-74. PubMed ID: 7575066
[TBL] [Abstract][Full Text] [Related]
43. Impact of epoetin-beta on survival of patients with lymphoproliferative malignancies: long-term follow up of a large randomized study.
Osterborg A; Brandberg Y; Hedenus M
Br J Haematol; 2005 Apr; 129(2):206-9. PubMed ID: 15813848
[TBL] [Abstract][Full Text] [Related]
44. Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51).
Johnson EA; Marks RS; Mandrekar SJ; Hillman SL; Hauge MD; Bauman MD; Wos EJ; Moore DF; Kugler JW; Windschitl HE; Graham DL; Bernath AM; Fitch TR; Soori GS; Jett JR; Adjei AA; Perez EA
Lung Cancer; 2008 May; 60(2):200-7. PubMed ID: 18045731
[TBL] [Abstract][Full Text] [Related]
45. Weekly epoetin alfa treatment of anemia in patients with cancer not undergoing therapy.
Shasha D; Williams D
J Support Oncol; 2006 Mar; 4(3):129-35. PubMed ID: 16553139
[TBL] [Abstract][Full Text] [Related]
46. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
[TBL] [Abstract][Full Text] [Related]
47. Experience with epoetin alfa and acquired immunodeficiency syndrome anemia.
Henry DH
Semin Oncol; 1998 Jun; 25(3 Suppl 7):64-8. PubMed ID: 9671334
[TBL] [Abstract][Full Text] [Related]
48. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial.
Littlewood TJ; Bajetta E; Nortier JW; Vercammen E; Rapoport B;
J Clin Oncol; 2001 Jun; 19(11):2865-74. PubMed ID: 11387359
[TBL] [Abstract][Full Text] [Related]
49. Therapeutic equivalence, long-term efficacy and safety of HX575 in the treatment of anemia in chronic renal failure patients receiving hemodialysis.
Haag-Weber M; Vetter A; Thyroff-Friesinger U;
Clin Nephrol; 2009 Nov; 72(5):380-90. PubMed ID: 19863881
[TBL] [Abstract][Full Text] [Related]
50. Once-weekly epoetin beta therapy in patients with solid tumours and chemotherapy-induced anaemia: a randomized, double-blind, dose-finding study.
Heras P; Kritikos K; Hatzopoulos A; Mitsibounas D
Eur J Cancer Care (Engl); 2008 Nov; 17(6):619-23. PubMed ID: 18707619
[TBL] [Abstract][Full Text] [Related]
51. Double-blind, placebo-controlled study of quality of life, hematologic end points, and safety of weekly epoetin alfa in children with cancer receiving myelosuppressive chemotherapy.
Razzouk BI; Hord JD; Hockenberry M; Hinds PS; Feusner J; Williams D; Rackoff WR
J Clin Oncol; 2006 Aug; 24(22):3583-9. PubMed ID: 16877725
[TBL] [Abstract][Full Text] [Related]
52. Recombinant human erythropoietin in pediatric oncology: a review.
Feusner J; Hastings C
Med Pediatr Oncol; 2002 Oct; 39(4):463-8. PubMed ID: 12203665
[TBL] [Abstract][Full Text] [Related]
53. Epoetin delta is effective for the management of anaemia associated with chronic kidney disease.
Spinowitz BS; Pratt RD;
Curr Med Res Opin; 2006 Dec; 22(12):2507-13. PubMed ID: 17166333
[TBL] [Abstract][Full Text] [Related]
54. Epoetin alpha prevents anaemia and reduces transfusion requirements in patients undergoing primarily platinum-based chemotherapy for small cell lung cancer.
Thatcher N; De Campos ES; Bell DR; Steward WP; Varghese G; Morant R; Vansteenkiste JF; Rosso R; Ewers SB; Sundal E; Schatzmann E; Stocker H
Br J Cancer; 1999 May; 80(3-4):396-402. PubMed ID: 10408844
[TBL] [Abstract][Full Text] [Related]
55. [Improvement of anemia and quality of life of patients with prostate cancer by treatment with human recombinant erythropoietin].
Queipo Zaragozá JA; Chicote Pérez F; Beltrán Meseguer JF; Borrell Palanca A; Giner Marco V; Esteve Claramunt J; Pastor Sempere F
Arch Esp Urol; 2004; 57(1):35-40. PubMed ID: 15112869
[TBL] [Abstract][Full Text] [Related]
56. Once-weekly epoetin beta (30,000 IU) in anemic patients with lung cancer receiving chemotherapy.
Pirker R; Lehnert M; Minar W
Lung Cancer; 2007 Jan; 55(1):89-94. PubMed ID: 17084484
[TBL] [Abstract][Full Text] [Related]
57. Does anemia affect outcome after lobectomy or pneumonectomy in early stage lung cancer patients who have not received neo-adjuvant treatment?
Chamogeorgakis T; Anagnostopoulos C; Kostopanagiotou G; Bhora F; Toumpoulis I; Georgiannakis E; Nabong A; Dosios T; Harrison L; Connery C
Thorac Cardiovasc Surg; 2008 Apr; 56(3):148-53. PubMed ID: 18365973
[TBL] [Abstract][Full Text] [Related]
58. Role of epoetin in the management of anaemia in patients with lung cancer.
Morère JF
Lung Cancer; 2004 Nov; 46(2):149-56. PubMed ID: 15474662
[TBL] [Abstract][Full Text] [Related]
59. Effects of early intervention with epoetin alfa on transfusion requirement, hemoglobin level and survival during platinum-based chemotherapy: Results of a multicenter randomised controlled trial.
Savonije JH; van Groeningen CJ; van Bochove A; Honkoop AH; van Felius CL; Wormhoudt LW; Giaccone G
Eur J Cancer; 2005 Jul; 41(11):1560-9. PubMed ID: 15953714
[TBL] [Abstract][Full Text] [Related]
60. Epoetin alfa use in gynecology. Past, present and future.
Bachmann GA
J Reprod Med; 2001 May; 46(5 Suppl):539-44. PubMed ID: 11396388
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
